Statement of deviation(s) or variation(s) under Reg. 32

Date: July 27, 2026 To, To, Sr. General Manager Sr. General Manager BSE Limited National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Submission of statement of Deviation or Variation in utilisation of funds of public issue for quarter ended on June 30, 2026 Dear Sir/Madam, Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024 and SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 , please find enclosed herewith the statement of deviation(s) or variation(s) in utilisation of funds raised through Initial Public Offer (“IPO”) by the Company for the quarter ended June 30, 2026. We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of proceeds of IPO for the abovementioned period as mentioned in the objects stated in the Prospectus dated December 24, 2024. The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on July 27, 2026. This intimation is also being uploaded on the website of the Company i.e. www.senorespharma.com. You are requested to take the same on record. TFohra nSkeinnogr yeosu P. harmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Enclosure : As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH IPO, FOR THE QUARTER ENDED JUNE 30, 2026 Name of listed entity Mode of Fund Raising Senores Pharmaceuticals Limited Date of Raising Funds Initial Public offer Amount Raised December 26, 2024 Report filed for Quarter ended Rs. 500 Crores Monitoring Agency June 30, 2026 Monitoring Agency Name, if applicable Applicable Is there a Deviation / Variation in use of CARE Ratings Limited funds raised If yes, whether the same is pursuant to change in terms of a contract or objects, Not Applicable which was approved by the shareholders If Yes, Date of shareholder Approval Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after Not Applicable review No comments Comments of the auditors, if any No comments Objects for which funds have been raised and where there has been a deviation, in the (₹ in Crores) following table Original Object Modified Original Modified Funds Amount of Remarks, if Object, if Allocation Allocation, Utilized Deviation/ any any if any Variation for the quarter according to applicable object Investment in Not 107.00 Not 6.98 Not Applicable There is on- one of our Applicable Applicable going delay Subsidiaries, in Havix, to fund deployment capital of funds expenditure under requirements for object-1. setting up a Now, the manufacturing company facility for the has sought production of shareholder sterile injections approval for in our Atlanta variation in Senores Pharmaceuticals Limited Facility the objects / 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 terms of utilisation of proceeds extension of time limit through postal ballot. Re-payment/pre- Not 73.48 73.10 73.10 Not Applicable The payment, in full Applicable unutilized or in part, of amount of certain Rs. 0.38 borrowings crore has availed by our been Company transferred to GCP as resolved in the Board Meeting dated July 23, 2025. Investment in our Not 20.22 20.20 20.20 Not Applicable The Subsidiary, Applicable unutilized namely, Havix, amount of for re- Rs. 0.02 payment/pre- crore has payment in full or been in part, of certain transferred borrowings to GCP as availed by such resolved in Subsidiaries the Board Meeting dated July 23, 2025. Funding the Not 43.26 Not 43.26 Not Applicable - working capital Applicable Applicable requirements of our Company Investment in Not 59.48 Not 59.48 Not Applicable - our Subsidiaries, Applicable Applicable namely, SPI and Ratnatris to fund their working capital requirements Funding Not 154.37 161.91 161.63 Not Applicable Amount of inorganic growth Applicable Rs. 7.54 through crore has Senores Pharmaceuticals Limited acquisition and been 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 other strategic transferred initiatives and from general Objective 2, corporate 3 and 7. purposes Offer expenses Not 42.19 35.04 34.80 Not Applicable The Applicable unutilized amount of Rs. 6.31 crore under objective-7 has been transferred to objective- 6 as resolved in the Board Meeting dt. March 28, 2026 and Rs. 0.84 crore as resolved in Board Meeting dt. Total 500.00 399.46 May 14. 2026 Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised; or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc For Senores Pharmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263